18 May 2020 - International reference pricing, by which drug prices would be pegged to international standards, is under consideration in the United States, although it could lead to adverse long-term consequences, according to a panel of health care and economic experts who discussed the prospect at the ISPOR annual meeting, Virtual ISPOR 2020, held this week.

International reference pricing may bring down the high cost of medicine for US consumers, but it could also stifle investment in new drug products because pharmaceutical companies would earn lower returns and have less money to invest in new medicines, said Lou Garrison, PhD, of the Comparative Health Outcomes, Policy, and Economics Institute Department of Pharmacy at the University of Washington in Seattle.

Read Center for Biosimilars article